骨髓增生异常综合征患者白血病干细胞的表达  

Expression of Leukemia Stem Cells in bone marrow of patients with myelodysplastic syndrome

作　　者：张红[1] 刘庆华[1] 田芳[1] 周丽[1] 

机构地区：[1]泰山医学院附属医院,山东泰安271000

出　　处：《泰山医学院学报》2014年第6期472-474,共3页Journal of Taishan Medical College

摘　　要：目的检测细胞表面抗原CD123(IL-3受体α链)在骨髓增生异常综合征(Myelodysplastic syndrome,MDS)患者骨髓中的表达,并探讨其与患者预后的关系。方法选择2010年11月至2012年8月在泰山医学院附属医院就诊的53例MDS患者及30例非恶性血液病患者骨髓标本,采用流式细胞术检测CD34+CD38-CD123+的表达情况;同时依据国际预后积分系统(IPSS)将MDS患者划分为低危组、中危-I组、中危-II组和高危组,分析CD34+CD38-CD123+的表达与MDS患者预后的相关性。结果 53例MDS患者骨髓CD34+CD38-CD123+/CD34+表达为14.29±7.89%,显著高于对照组的表达水平1.22±0.89%,t=9.013,P=0.000;其中高危组CD34+CD38-CD123+/CD34+的比例显著高于中危-I组和低危组,P<0.01;中危-II组显著高于低危组和中危-I组,P<0.01,中危-I组高于低危组,P<0.05。结论在MDS患者骨髓单个核细胞中CD123异常过度表达,有助于MDS的诊断及预后判断。Objective：To analyze the expression of CD123 in patients who are suffering from Myelodysplastic syndrome （MDS）,and explore the the clinical significance. Methods：The expression of CD123 in bone marrow was analyzed in 53 patients with MDS and 30 cases without malignant hematosis ,with direct immunofluorescence staining and flow cytometry.53 patients with MDS,who were divided into 4 groups of low - risk intermediate - riskI,intermediate - riskII and high -risk,respectively,according to International Prognostic Scoring System（ IPSS）. Results：Compared with that in control group ,positive expression rate of CD123 was higher in MDS group,t = 9. 013,P = 0. 000. The percent of CD34^＋ CD38^- CD123^＋ / CD34^＋ was higher in high - risk group than that in low - risk group and intermediate - riskI group（P ﹤ 0. 01）. The difference of positive rate of CD123 between intermediate - riskI group and intermediate - riskII group,intermediate -riskI group and low - risk group was all significant（P ﹤ 0. 05）. Conclusion Detection of CD123 may be an useful tool for diagnosis and predicting the prognosis of MDS.

关 键 词：细胞表面抗原 CD123 骨髓增生异常综合征 预后 流式细胞术 

分 类 号：R551.3[医药卫生—血液循环系统疾病]